598 related articles for article (PubMed ID: 17645586)
1. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Ahmed W; Ziouzenkova O; Brown J; Devchand P; Francis S; Kadakia M; Kanda T; Orasanu G; Sharlach M; Zandbergen F; Plutzky J
J Intern Med; 2007 Aug; 262(2):184-98. PubMed ID: 17645586
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Brown JD; Plutzky J
Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
[TBL] [Abstract][Full Text] [Related]
3. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
[TBL] [Abstract][Full Text] [Related]
4. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Gervois P; Fruchart JC; Staels B
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
6. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
7. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons.
Cimini A; Benedetti E; Cristiano L; Sebastiani P; D'Amico MA; D'Angelo B; Di Loreto S
Neuroscience; 2005; 130(2):325-37. PubMed ID: 15664689
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors and the metabolic syndrome.
Bragt MC; Popeijus HE
Physiol Behav; 2008 May; 94(2):187-97. PubMed ID: 18191967
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats.
Sun L; Ke Y; Zhu CY; Tang N; Tian DK; Gao YH; Zheng JP; Bian K
Chin Med J (Engl); 2008 Nov; 121(22):2305-11. PubMed ID: 19080338
[TBL] [Abstract][Full Text] [Related]
11. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
12. PPARs as therapeutic targets in cardiovascular disease.
van Bilsen M; van Nieuwenhoven FA
Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
[TBL] [Abstract][Full Text] [Related]
13. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
Zieleniak A; Wójcik M; Woźniak LA
Arch Immunol Ther Exp (Warsz); 2008; 56(5):331-45. PubMed ID: 18836859
[TBL] [Abstract][Full Text] [Related]
14. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
[TBL] [Abstract][Full Text] [Related]
15. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
16. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
[TBL] [Abstract][Full Text] [Related]
17. Effect of medium- and long-chain fatty acid diets on PPAR and SREBP-1 expression and glucose homeostasis in ACBP-overexpressing transgenic rats.
Oikari S; Ahtialansaari T; Huotari A; Kiehne K; Fölsch UR; Wolffram S; Jänne J; Alhonen L; Herzig KH
Acta Physiol (Oxf); 2008 Sep; 194(1):57-65. PubMed ID: 18394026
[TBL] [Abstract][Full Text] [Related]
18. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
[TBL] [Abstract][Full Text] [Related]
19. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Gross B; Staels B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
Guan Y
J Am Soc Nephrol; 2004 Nov; 15(11):2801-15. PubMed ID: 15504933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
